Risankizumab autoinjector for psoriasis treatment
Hand holding a risankizumab autoinjector pen. Marketed as Skyrizi, Risankizumab is a humanised monoclonal antibody that binds to interleukin 23A (IL-23A) and blocks the activity of pro-inflammatory cytokines. Risankizumab is used to treat moderate to severe plaque psoriasis and active psoriatic arthritis., by DR P. MARAZZI/SCIENCE PHOTO LIBRARY
Details
License type
Rights Managed